Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Breast Neoplasms 72Neoplasms 64Prostatic Neoplasms 45Colorectal Neoplasms 42Lung Neoplasms 38Carcinoma, Non-Small-Cell Lung 26Pancreatic Neoplasms 21Neoplasm Metastasis 20Hematologic Neoplasms 20Head and Neck Neoplasms 20Urinary Bladder Neoplasms 15Ovarian Neoplasms 14Multiple Myeloma 11Motor Activity 11Leukemia, Myeloid, Acute 11Stomach Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Uterine Cervical Neoplasms 9Triple Negative Breast Neoplasms 9Glioblastoma 9Colonic Neoplasms 9Hematopoietic and Lymphatic System Neoplasm 8Glioma 8Gastrointestinal Neoplasms 8Carcinoma, Renal Cell 8COVID-19 8Anxiety Disorders 8Anatomic Stage I Breast Cancer AJCC v8 8Rectal Neoplasms 7Melanoma 7

Interventions

Peripheral Blood Stem Cell Transplantation 4Cyclophosphamide 4Epoetin Alfa 3Darbepoetin alfa 3Curcumin 3liposomal amphotericin B 2fludarabine phosphate 2Morphine 2Methylprednisolone 2Interferon-alpha 2Filgrastim 2Cyclosporine 2Caspofungin 2Carboplatin 2Bortezomib 2Antilymphocyte Serum 2tanespimycin 1siltuximab 1sargramostim 1pyroxamide 1piperine 1isatuximab 1ibrutinib 1ferrous sulfate 1ferric gluconate 1alethine 1aldesleukin 1Whole-Body Irradiation 1Topotecan 1Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Monoclonal Gammopathy of Undetermined Significance × Standard of Care × Clear all
NCT04439006 2023-12-26

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
10 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Aplastic, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndromes, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡